News

Merck's Verona Acquisition: Plugging A $4B Hole In A $20B Gap
Merck’s recent acquisition announcement sends a strong signal regarding its urgency to tackle the impending Keytruda patent ...
MONTCO Today on MSN12h
WSJ: Merck Makes $10 Billion Move as Keytruda Patent Expiration Nears
Merck is making big pharma waves again with a $10 billion deal to acquire Verona Pharma, reports Colin Kellaher for the Wall ...
Zacks.com on MSN1d
Merck's VRNA Buyout to Add Novel COPD Therapy: How to Play the Stock?
MRK's $10B buyout of VRNA brings in Ohtuvayre, a unique COPD therapy set to bolster its cardio-pulmonary portfolio.
Merck Faces Multiple Challenges: Will It Steer Through Successfully?
MRK banks on new launches as Keytruda faces a looming patent cliff and Gardasil weakens amid China's demand slump.
Merck to Buy Verona for $10 Billion as Patent Cliff Looms
Merck & Co. agreed to buy respiratory drugmaker Verona Pharma Plc for around $10 billion as part of its ongoing search for ...
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
STAT3d
Pharmalittle: We’re reading about Trump’s latest tariff threat, a Merck deal, and lots more
President Trump threatened to impose up to 200% tariffs on pharmaceuticals imported into the U.S., but not immediately ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...